Intelligence · Clinical Development
Pipeline search results
Programs matching “multiple-myeloma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 167 pipeline programs matching "multiple-myeloma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Selinexor
Karyopharm Therapeutics Inc
Refractory Multiple Myeloma
1 trial -
TAK-079
Takeda
Multiple Myeloma
1 trial -
TAK-573
Teva Pharma GmbH
Relapsed and/or Refractory Multiple Myeloma
1 trial -
Tabalumab
Eli Lilly and Company
Multiple Myeloma
1 trial -
Y150
Wuhan YZY Biopharma Co.,
Relapsed or Refractory Multiple Myeloma
1 trial -
YTS104 Cells injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed or Refractory Multiple Myeloma
1 trial -
agenT-797
MiNK Therapeutics
Relapsed/Refractory Multiple Myeloma
1 trial -
pomalidomide
Celgene Europe Limited
Multiple Myeloma in Relapse
1 trial -
Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
Ixazomib
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
Ixazomib
Takeda
Relapsed and/or Refractory Multiple Myeloma
4 trials -
K9520
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
SHCZH-2010-CT-001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
SZ5202
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
Tocilizumab
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
melphalan hydrochloride for injection
CASI Pharmaceuticals
Multiple Myeloma
2 trials -
18F-PSMA-1007
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
BCMA-CART
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
CT0590 CAR T Cells
The First People's Hospital of Lianyungang
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CT0594CP
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
LCAR- F33S cells intravenous infusion
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Multiple Myeloma(MM)
1 trial -
LCAR-M61S cells preparation
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
PD1-BCMA-CART
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.